Hipolin Ltd has announced the approval of its quarterly financial results for the third quarter of fiscal year 2026. The company's Board of Directors convened on February 14, 2026, to review and approve key financial documents in accordance with regulatory requirements.

Board Meeting Outcome

The board meeting was held on Saturday, February 14, 2026, where directors considered and approved both standalone and consolidated unaudited financial results for the quarter ended December 31, 2025. The meeting was conducted with specific timing parameters as outlined in the regulatory filing.

Financial Results Approval

The primary agenda item involved the consideration and approval of the company's financial performance for the quarter ended December 31, 2025. The board approved both standalone and consolidated unaudited financial results, ensuring comprehensive coverage of the company's financial position.

The approved financial results include a Limited Review Report provided by the company's Statutory Auditor, adding an additional layer of verification to the financial data. This review report accompanies the unaudited results as part of the standard regulatory compliance process.

Regulatory Compliance and Filing

The announcement was made pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The company filed this information with BSE Limited under scrip code 530853 and scrip ID HIPOLIN, ensuring proper disclosure to market participants and regulatory authorities.

The filing was signed by Anjali Maheshwari, who serves as the Company Secretary and Compliance Officer for Hipolin Ltd. The digital signature was applied on February 14, 2026, at 18:18:57 +05'30', confirming the authenticity and timing of the regulatory submission to BSE Limited at Dalal Street, Fort, Mumbai.

Hipolin Limited , a detergent manufacturing company, has announced its financial results for the second quarter of the fiscal year 2026, ending September 30, 2025. The company's performance indicates continued challenges in its operations.

Key Financial Highlights

Revenue and Profitability

Hipolin Limited reported a revenue from operations of Rs 318.08 lacs for the quarter, marking a significant decrease from Rs 552.36 lacs in the corresponding quarter of the previous fiscal year. The total income for Q2 FY2026 stood at Rs 323.15 lacs, compared to Rs 563.20 lacs in Q2 FY2025.

Expenses and Net Loss

The company's total expenses for the quarter amounted to Rs 322.69 lacs, lower than the Rs 601.64 lacs reported in the same quarter last year. Despite the reduction in expenses, Hipolin Limited posted a net loss of Rs 73.12 lacs for Q2 FY2026, which is higher than the net loss of Rs 38.44 lacs recorded in Q2 FY2025.

Operational Performance

The increased net loss, despite lower expenses, suggests that Hipolin Limited may be facing challenges in its core operations. The company's primary business remains the manufacturing of detergent powder and cake, which falls within a single business segment.

Board Approval and Audit Review

The unaudited financial results were approved by Hipolin Limited's Board of Directors in a meeting held on November 14, 2025. The company's statutory auditors have conducted a limited review of these results and have issued an unmodified review report.

Consolidated Results

On a consolidated basis, which includes the results of its subsidiary Jayantilal Bhogilal Chemicals Private Limited, Hipolin Limited reported similar figures, with a net loss of Rs 73.06 lacs for the quarter.

Balance Sheet Position

As of September 30, 2025, Hipolin Limited's total assets stood at Rs 986.57 lacs, down from Rs 1,297.64 lacs at the end of the previous fiscal year. The company's equity share capital remained unchanged at Rs 313.13 lacs.

Cash Flow

The company's cash and cash equivalents decreased from Rs 28.11 lacs at the beginning of the period to Rs 1.82 lacs by the end of Q2 FY2026, indicating a tightening of liquidity.

Investors and stakeholders will be watching closely to see how Hipolin Limited addresses its ongoing losses and improves its operational performance in the coming quarters.